Home › Funds › ORBIMED ADVISORS LLC › ASND
ORBIMED ADVISORS LLC position in ASND
ASCENDIS PHARMA A/S · Health Care
ORBIMED ADVISORS LLC reported holding 244,456 shares of ASND (ASCENDIS PHARMA A/S) in its Q2 2026 13F filing — a position valued at US$65.2M, representing 1.31% of its reported portfolio and ranking #21 among its reported holdings. ORBIMED ADVISORS LLC has disclosed ASND holdings in 5 of the last 5 reported quarters, going back to Q2 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How ORBIMED ADVISORS LLC's ASND position evolved
ORBIMED ADVISORS LLC first disclosed a stake in ASND in Q2 2025 at 34,400 shares (US$5.9M). The position peaked in Q2 2026 at 244,456 shares, worth US$65.2M. Across 5 filings, ORBIMED ADVISORS LLC increased the stake 3 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 244,456 shares valued at US$65.2M — an increase of 62,479 shares quarter over quarter.. Notable position changes include a 458% increase in Q3 2025 (shares rose 7% over the following quarter), a 34% increase in Q2 2026 (shares fell 15% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2025 | 34.40K | $5.94M | New |
| Q3 2025 | 191.91K | $38.15M | Add |
| Q4 2025 | 171.98K | $36.67M | Reduce |
| Q1 2026 | 181.98K | $41.62M | Add |
| Q2 2026 | 244.46K | $65.20M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ASND and 13F data
ASND (ASCENDIS PHARMA A/S) is a Health Care company. 42 other funds we track also report a position in ASND — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$2.74B), T. Rowe Price Investment Management, Inc. (US$1.80B), Avoro Capital Advisors LLC (US$1.36B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ASND
- RA CAPITAL MANAGEMENT, L.P. 10.28M sh · $2.74B · Q2 2026
- T. Rowe Price Investment Management, Inc. 6.75M sh · $1.80B · Q2 2026
- Avoro Capital Advisors LLC 5.11M sh · $1.36B · Q2 2026
- WESTFIELD CAPITAL MANAGEMENT CO LP 4.80M sh · $1.28B · Q2 2026
- Jupiter Topco LLC 3.65M sh · $973.38M · Q2 2026
- Artisan Partners Limited Partnership 2.63M sh · $702.55M · Q2 2026
- PERCEPTIVE ADVISORS LLC 1.16M sh · $310.39M · Q2 2026
- Vestal Point Capital, LP 375.00K sh · $100.02M · Q2 2026
- Tri Locum Partners LP 258.74K sh · $69.01M · Q2 2026
- PFM Health Sciences, LP 233.17K sh · $62.19M · Q2 2026
- Frazier Life Sciences Management, L.P. 225.16K sh · $60.05M · Q2 2026
- Spyglass Capital Management LLC 215.40K sh · $57.45M · Q2 2026
More on ORBIMED ADVISORS LLC
FAQ
How long has ORBIMED ADVISORS LLC held ASND?
ORBIMED ADVISORS LLC has disclosed ASND holdings in 5 of the last 5 reported quarters, going back to Q2 2025.
What is ORBIMED ADVISORS LLC's current position in ASND?
As of Q2 2026, ORBIMED ADVISORS LLC holds 244.46K shares of ASND (ASCENDIS PHARMA A/S), valued at $65.20M, representing 1.31% of its reported portfolio and ranking #21.
Has ORBIMED ADVISORS LLC been buying or selling ASND?
In the latest 13F filing (Q2 2026), ORBIMED ADVISORS LLC increased its position in ASND. The position peaked in Q2 2026 at 244.46K shares.
Which other funds hold ASND?
Other major institutional holders of ASND include RA CAPITAL MANAGEMENT, L.P., T. Rowe Price Investment Management, Inc., Avoro Capital Advisors LLC, among 42 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.